Experimental models of epilepsy are useful to identify potential mechanisms of
epileptogenesis, seizure genesis, comorbidities, and treatment efficacy. The kainic acid (KA) …

Rationally designed multi-target drugs (also termed multimodal drugs, network therapeutics,
or designed multiple ligands) have emerged as an attractive drug discovery paradigm in the …

Antiseizure drugs (ASDs), also termed antiepileptic drugs, are the main form of symptomatic
treatment for people with epilepsy, but not all patients become free of seizures. The …

In many patients who suffer from epilepsies, recurrent epileptic seizures do not start at birth
but develop later in life. This holds particularly true for epilepsies with a focal seizure origin …

This article reviews the profile of perampanel, a novel noncompetitive α‐amino‐3‐hydroxyl‐
5‐methyl‐4‐isoxazole‐propionate (AMPA) receptor antagonist, and its role as a potential …

Since the 1990s, ionotropic glutamate receptors have served as an outstanding target for
drug discovery research aimed at the discovery of new neurotherapeutic agents. With the …

The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of
intensive research, causal treatment of this common neurologic disorder is still unavailable …

Pharmacological manipulation of specific neural circuits to optimize therapeutic index is an
unrealized goal in neurology and psychiatry. AMPA receptors are important for excitatory …

Background: A dysfunction in glutamate neurotransmission is critical for seizure. Glutamate
is the major excitatory drive in the cerebral cortex, where seizures occur. Glutamate acts via …

There is a growing body of clinical and experimental evidence that neurodegenerative
diseases and epileptogenesis after an acquired brain insult may share common etiological …